Who are Entecavir + Pegylated interferon α-2b's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/entecavir-pegylated-interferon-2b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Entecavir + Pegylated interferon α-2b — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Entecavir + Pegylated interferon α-2b (Entecavir + Pegylated interferon α-2b) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination (nucleoside reverse transcriptase inhibitor + immunomodulator). Area: Virology/Hepatology.

marketed Antiviral combination (nucleoside reverse transcriptase inhibitor + immunomodulator) HBV reverse transcriptase; interferon-α receptor Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Entecavir + Pegylated interferon α-2b (Entecavir + Pegylated interferon α-2b) — Qing-Lei Zeng. This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and pegylated interferon α-2b to enhance immune response against HBV-infected cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Entecavir + Pegylated interferon α-2b TARGET	Entecavir + Pegylated interferon α-2b	Qing-Lei Zeng	marketed	Antiviral combination (nucleoside reverse transcriptase inhibitor + immunomodulator)	HBV reverse transcriptase; interferon-α receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination (nucleoside reverse transcriptase inhibitor + immunomodulator) class)

Qing-Lei Zeng · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Entecavir + Pegylated interferon α-2b — Competitive Intelligence Brief. https://druglandscape.com/ci/entecavir-pegylated-interferon-2b. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab